Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502509 | 1.00 | MRGPRX4 (0.43) | MRGPRX4KDM4ENPSR1RXFP1LMNA | |
| SCHEMBL25281526 | 0.87 | KMT2A (0.49) | KDM4ELMNAALDH1A1MAPTGAA | |
| SCHEMBL25281527 | 0.87 | KMT2A (0.49) | KDM4ELMNAALDH1A1MAPTGAA | |
| SCHEMBL10580837 | 0.84 | POLB (0.47) | KDM4ELMNAALDH1A1MAPTGAA | |
| SCHEMBL20570498 | 0.82 | MAPT (0.46) | MRGPRX4KDM4ENPSR1RXFP1LMNA | |
| SCHEMBL28388204 | 0.82 | MAPT (0.46) | MRGPRX4KDM4ENPSR1RXFP1LMNA | |
| SCHEMBL23354713 | 0.80 | EGFR (0.43) | MRGPRX4KDM4ENPSR1RXFP1LMNA | |
| SCHEMBL3839304 | 0.79 | MAPT (0.54) | KDM4ENPSR1LMNAALDH1A1MAPT | |
| SCHEMBL3839303 | 0.79 | MAPT (0.54) | KDM4ENPSR1LMNAALDH1A1MAPT | |
| SCHEMBL10056749 | 0.79 | ABCB1 (0.53) | KDM4ELMNAALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106085-B2 | Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-31 | — | — | US | disclosed |
| US-7994200-B2 | Central nervous system disorders; respiratory system disorders; sexual or reproductive disorders; eating disorders; antidiabetic agents; cardiovascular disorders; anticancer agents | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-09 | — | — | US | disclosed |
| EP-2108012-A2 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-10-14 | — | — | EP | disclosed |
| EP-1641763-B1 | 4-CYANOPYRAZOLE-3-CARBOXAMIDE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20090131497-A1 | INDOLINE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| US-20090054509-A1 | Octahydropentalene-Substituted Pyrazoline Derivatives, Their Prepartion and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-02-26 | — | — | US | disclosed |
| US-20080293797-A1 | Cycloalkane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-11-27 | — | — | US | disclosed |
| US-20080269201-A1 | Azepane- or Azocane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-30 | — | — | US | disclosed |
| WO-2008099076-A2 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
| EP-1937668-A1 | OCTAHYDROPENTALENE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| EP-1910344-A2 | INDOLINE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910301-A2 | CYCLOALKANE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910339-A2 | AZEPANE- OR AZOCANE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009722-A1 | OCTAHYDROPENTALENE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009721-A2 | INDOLINE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009723-A2 | AZEPANE- OR AZOCANE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009724-A2 | CYCLOALKANE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| EP-1641763-A2 | 4-CYANOPYRAZOLE-3-CARBOXAMIDE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000820-A2 | 4-CYANOPYRAZOLE-3-CARBOXAMIDE DERIVATIVES PREPARATION AND APPLICATION THEREOF AS CB1 CANNABINOID ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293797-A1 | Cycloalkane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments | PIGO, BDKRB2, FPR1 | MRGPRX4 95/4885KDM4E 4558/4885NPSR1 849/4885 |
| US-20080269201-A1 | Azepane- or Azocane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments | AZI2, CYP3A43, ALPI | MRGPRX4 158/4885KDM4E 1365/4885NPSR1 490/4885 |
| US-20090054509-A1 | Octahydropentalene-Substituted Pyrazoline Derivatives, Their Prepartion and Use as Medicaments | CYP11B2, OTC, OAT | MRGPRX4 382/4885KDM4E 4099/4885NPSR1 615/4885 |
| US-20090131497-A1 | INDOLINE-SUBSTITUTED PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | IDO1, PIR, INMT | MRGPRX4 1061/4885KDM4E 2806/4885NPSR1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.